Cagrilintide
Janoshik
Batch CAG-CA-26A-01
Cagrilintide
Amylin Receptor Research Peptide
Cagrilintide is a long-acting amylin analogue studied in laboratory research for its interaction with metabolic signaling pathways. Researchers investigate how it influences biochemical systems involved in nutrient regulation, satiety signaling, and glucose-related metabolic processes. It is commonly used in experimental studies exploring peptide activity in metabolic pathway research.
This product is intended strictly for laboratory research use within the United States. It is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable U.S. federal, state, and local regulations.
Cagrilintide is a synthetic peptide developed for controlled laboratory research involving amylin receptor signaling systems. It is structurally designed to interact with amylin-associated pathways within experimental environments.
In scientific literature, cagrilintide is studied in models examining receptor-mediated signaling cascades, metabolic pathway interaction, and downstream cellular response systems under in vitro and preclinical research conditions.
Third-party tested for purity, ID, quantity.
Cagrilintide is a long-acting synthetic amylin analogue evaluated in research focused on amylin receptor activity and associated signaling pathways. Experimental studies examine receptor interaction models, endocrine-related signaling systems, and pathway-level regulatory mechanisms.
Preclinical and clinical research publications have explored its receptor-binding characteristics and downstream signaling behavior within controlled study environments.
Cagrilintide was developed through research efforts aimed at modifying native amylin analogues to extend receptor interaction duration and signaling stability. Investigations into amylin pathway modulation led to the synthesis of long-acting peptide analogues for experimental evaluation.
Subsequent research publications documented its receptor-binding profile and signaling activity within laboratory and clinical research frameworks.
Laboratory investigations into cagrilintide have focused on amylin receptor interaction models and downstream signaling pathways. Research frameworks evaluate receptor activation dynamics, endocrine-related regulatory systems, and metabolic signaling environments under controlled in vitro and preclinical conditions.
0 of the 4 areas below are addressed directly by a paper cited on this page.
Amylin receptor activation models
No paper cited on this page reports on amylin, receptor or activation. This heading marks where Cagrilintide is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Endocrine signaling pathway research
No paper cited on this page reports on endocrine. This heading marks where Cagrilintide is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Long-acting peptide analogue evaluation
No paper cited on this page reports on long, acting or peptide. This heading marks where Cagrilintide is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Metabolic regulatory framework studies
No paper cited on this page reports on metabolic. This heading marks where Cagrilintide is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
The references section of this page cites 2 primary papers published in 2025 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for Cagrilintide, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
Cagrilintide is also referred to as cagri.
Cagrilintide is commonly described online in connection with weight loss, appetite suppression and fat reduction. In the research literature the same compound is filed under amylin receptor activation models, endocrine signaling pathway research and long-acting peptide analogue evaluation.
The 2 papers cited on this page, published between 2025 and 2025 describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Presented alongside compounds with decades of published research, as though the evidence base is comparable.
It is not. Cagrilintide rests on 2 cited papers (between 2025 and 2025). A record that thin cannot support conclusions about mechanism, effect or safety, and the honest reading is that this compound has been studied very little rather than studied and validated.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for Cagrilintide is per lot, not per product. The current 5mg lot CAG-CA-26A-01 returned 99.446% purity, 5.62 mg measured, 112.4% of the labelled 5 mg, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.
Purity is half the number. It states what fraction of the material in the vial is Cagrilintide; it says nothing about how much material is in the vial, and a short-filled vial can return a purity result that is entirely accurate. The figure that answers the second question is measured mass against expected content — for Cagrilintide, this lot measured 112.4% of its labelled 5 mg. Both numbers are published for every lot, whichever way they fall.
The lot code printed on the vial matches the code on the certificate for Cagrilintide. Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.
Researchers who buy Cagrilintide in the United States through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
- Lyophilized storage
- −20 °C long-term; stable at room temperature in transit
- After reconstitution
- 2–8 °C
- Light
- Protect from UV and direct light
- Freeze-thaw
- Avoid repeated cycles
- Vehicle
- Bacteriostatic water in most published protocols
- Format
- Lyophilized powder
Cagrilintide is supplied as lyophilized powder. In the dry state the material is comparatively stable, which is why it ships at ambient temperature without a cold chain; once reconstituted it is a peptide in solution and the handling constraints tighten considerably. At 37 residues it is short enough to be produced by solid-phase synthesis, and the published sequence on this page is what an identity assay is checked against.
Repeated freeze-thaw cycling is the handling error most likely to degrade material of this class, because each cycle concentrates solutes at the ice boundary. Where a protocol calls for the same vial across multiple sessions, the published literature generally describes aliquoting after reconstitution rather than re-freezing the whole volume.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
- 1 × sealed glass vial in the strength selected (10mg / Single Vial, 10mg / 5-Pack, 10mg / 10-Pack available), batch-labelled
- The batch-linked Certificate of Analysis for the exact lot shipped
- Discreet outer packaging with no product names on the exterior
- FedEx, tracked, typically 1–3 business days domestically
- Bacteriostatic water or any other reconstitution vehicle
- Syringes, needles or filters
- Dosing, administration or protocol guidance of any kind
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each vial contains 5mg of lyophilized cagrilintide. Independent third-party testing verifies purity, identity, and net content per batch.
The vial contains only the lyophilized peptide. Any laboratory materials required for experimental procedures must be sourced separately.
Duration depends entirely on research protocol, storage conditions, and laboratory application.
Related
You May Also Like
Next-generation GLP receptor agonist studied for metabolic signaling and nutrient partitioning pathways
From$79.99
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
From$39.99
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
From$59.99
Pentadecapeptide studied for angiogenesis signaling, tissue repair pathways, and cellular regeneration research
From$49.99